-
公开(公告)号：US20200079861A1
公开(公告)日：2020-03-12
申请号：US15781043
申请日：2016-12-02
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Takemasa TSUJI , Olivier LÉGER , Dennis J. Underwood , Marc VAN DIJK
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US20190010239A1
公开(公告)日：2019-01-10
申请号：US15962673
申请日：2018-04-25
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Ana M. GONZALEZ , Nicholas S. WILSON , Dennis J. UNDERWOOD , Volker SEIBERT , Olivier LÉGER , Marc VAN DIJK , Roberta ZAPPASODI , Taha MERGHOUB , Jedd David WOLCHOK , David SCHAER , Gerd RITTER , Takemasa TSUJI
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
-
公开(公告)号：US20180355051A1
公开(公告)日：2018-12-13
申请号：US15962752
申请日：2018-04-25
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Ana M. GONZALEZ , Nicholas S. WILSON , Dennis J. UNDERWOOD , Volker SEIBERT , Olivier LÉGER , Marc VAN DIJK , Roberta ZAPPASODI , Taha MERGHOUB , Jedd David WOLCHOK , David SCHAER , Gerd RITTER , Takemasa TSUJI
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
-
公开(公告)号：US20210171648A1
公开(公告)日：2021-06-10
申请号：US17077456
申请日：2020-10-22
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Takemasa TSUJI , Olivier LÉGER , Dennis J. UNDERWOOD , Marc VAN DIJK
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US20210070872A1
公开(公告)日：2021-03-11
申请号：US16999374
申请日：2020-08-21
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Volker SEIBERT , Olivier LÉGER , Marc VAN DIJK , Taha MERGHOUB , David SCHAER , Gerd RITTER , Takemasa TSUJI
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
-
公开(公告)号：US20190062446A1
公开(公告)日：2019-02-28
申请号：US16175453
申请日：2018-10-30
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Volker SEIBERT , Olivier LÉGER , Marc VAN DIJK , Taha MERGHOUB , David SCHAER , Gerd RITTER , Takemasa TSUJI
摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
-
公开(公告)号：US20220372149A1
公开(公告)日：2022-11-24
申请号：US17662518
申请日：2022-05-09
申请人： AGENUS INC. , LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , MEMORIAL SLOAN-KETTERING CANCER CENTER
发明人： Marc VAN DIJK , Cornelia Anne MUNDT , Gerd RITTER , Jedd David WOLCHOK , Taha MERGHOUB , Roberta ZAPPASODI , Rikke Baek HOLMGAARD , David SCHAER , David Adam SAVITSKY , Nicholas Stuart WILSON
IPC分类号： C07K16/28 , A61P35/00 , A61K45/06 , A61K39/395
摘要： The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
-
公开(公告)号：US20220098316A1
公开(公告)日：2022-03-31
申请号：US17446706
申请日：2021-09-01
申请人： AGENUS INC. , Ludwig Institute for Cancer Research Ltd. , Memorial Sloan-Kettering Cancer Center
发明人： Marc VAN DIJK , Ekaterina V. Breous-Nystrom , Volker Seibert , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Jeremy Waight , Nicholas S. Wilson
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , G01N33/68
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US20200317797A1
公开(公告)日：2020-10-08
申请号：US16906587
申请日：2020-06-19
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. WILSON , Jeremy D. WAIGHT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Takemasa TSUJI , Olivier LÉGER , Dennis J. UNDERWOOD , Marc VAN DIJK
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US20200317796A1
公开(公告)日：2020-10-08
申请号：US16808074
申请日：2020-03-03
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Marc VAN DIJK , Ekaterina V. BREOUS-NYSTROM , Volker SEIBERT , Gerd RITTER , David SCHAER , Daniel HIRSCHHORN-CYMERMAN , Taha MERGHOUB , Hao TANG , David A. SAVITSKY , Jeremy WAIGHT , Nicholas S. WILSON
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , G01N33/68
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.033 秒)
